Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Common Equity (2020 - 2025)

iSpecimen has reported Common Equity over the past 6 years, most recently at $3.1 million for Q4 2025.

  • For Q4 2025, Common Equity fell 6.73% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, down 6.73%, while the annual FY2025 figure was $3.1 million, 6.73% down from the prior year.
  • Common Equity for Q4 2025 was $3.1 million at iSpecimen, up from $3.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $29.8 million in Q4 2021 and troughed at -$31.2 million in Q1 2021.
  • A 5-year average of $10.1 million and a median of $10.2 million in 2021 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 209.21% in 2021 and later crashed 89.79% in 2025.
  • Year by year, Common Equity stood at $29.8 million in 2021, then crashed by 31.83% to $20.3 million in 2022, then tumbled by 52.04% to $9.7 million in 2023, then crashed by 66.01% to $3.3 million in 2024, then decreased by 6.73% to $3.1 million in 2025.
  • Business Quant data shows Common Equity for ISPC at $3.1 million in Q4 2025, $3.1 million in Q3 2025, and $621973.0 in Q2 2025.